Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)

Active
Yes
Status
Posted
Published Date
June 14th, 2022
Close Date
September 7th, 2025
Award Ceiling
$275,000.00
Opportunity No.
PAR-22-199

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health is offering a grant opportunity titled "Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)". This grant aims to support research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit for the development of new and effective anticancer treatments. The grant does not require cost sharing or matching. The maximum award ceiling is $275,000. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities, Indian/Native American Tribal Governments, Non-domestic (non-U.S.) Entities, Regional Organizations, Tribally Controlled Colleges and Universities, and U.S. Territories or Possessions. The closing date for applications is September 7, 2025. For more information and to apply, visit the following link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html. For any inquiries, contact NIH OER Webmaster at OERWebmaster03@od.nih.gov.

Description

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will solicit R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)". This grant aims to solicit research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the PAIRS program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit towards building new and effective anticancer treatments. The grant does not require cost sharing or matching requirements. The funding instrument type is a grant, and the category of funding activity is health. The opportunity falls under the discretionary category and has a CFDA number of 93.395. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The grant opportunity will close on September 7, 2025, and the last updated date was June 14, 2022. For more information and inquiries, interested parties can visit the additional information URL provided: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html).
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)". This grant aims to support pre-clinical research projects that utilize advanced cancer biology methods and model systems to study the effects of radiopharmaceutical therapy (RPT) agents on normal tissue, tumor cells, and the tumor microenvironment. The goal is to understand how RPT dynamically impacts cancer biology processes, which can inform the development of new targeting strategies and approaches for clinical trials. The grant does not require cost sharing or matching and falls under the category of funding activity for health. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for applications is May 7, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-140.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-140.html). For any inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)". This grant aims to support the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials. It also includes correlative studies associated with clinical trials, novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations. Additionally, innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, are encouraged, as they could lead to first-in-human clinical trials. The R21 mechanism provides support for the early and conceptual stages of these projects, which may involve considerable risk but have the potential to make breakthroughs in cancer research. The grant has a funding ceiling of $275,000 and does not require cost sharing or matching. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The closing date for applications is July 1, 2025. For more information and to apply, visit the following link: [NCI Clinical and Translational Exploratory/Developmental Studies Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-22-216.html).
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)". This grant aims to support research projects that utilize advanced cancer biology methods and model systems to study the effects of different types of radiation used in radionuclide-based therapeutics on normal tissue, tumor cells, and the tumor microenvironment. The funding instrument for this opportunity is a grant, and it falls under the category of funding activity related to health. The grant does not require cost sharing or matching. The maximum award ceiling for this grant is $500,000. Eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for applications is May 7, 2025. For more information and to apply, please visit the following link: [Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-22-139.html). For any inquiries, please contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.